Read the evidence, not the hype
Tesamorelin vs Sermorelin: Uses and Evidence
Tesamorelin and sermorelin are often grouped because both relate to growth-hormone-releasing hormone pathways. Their regulatory histories and the populations studied, however, are not interchangeable. Tesamorelin is currently marketed as EGRIFTA WR for a narrow HIV-associated lipodystrophy indication. Sermorelin’s former U.S. products, Geref, were discontinued and FDA later found that the discontinuations were not for safety or effectiveness reasons. That finding does not create a current sermorelin approval or establish evidence for uses outside the former labeled populations.
Educational content — not medical advice. A commercial listing, biological mechanism, or laboratory result does not establish a safe or effective treatment. This page does not recommend a product, dose, stack, or provider.
The key takeaway
The meaningful distinction is evidence scope. Tesamorelin has a current FDA label and controlled trial evidence for reducing excess abdominal fat in HIV-infected adults with lipodystrophy, while the label specifically says it is not a weight-loss treatment. Sermorelin has historical FDA approvals in specific pediatric growth-failure and pituitary-evaluation settings, but Geref is discontinued. Neither history supports general weight loss or anti-aging claims.
At-a-glance comparison
Compare the specific molecule, evidence, and indication. This is not a ranking or a treatment-selection tool.
| Question | Tesamorelin | Sermorelin |
|---|---|---|
| Current U.S. regulatory status | EGRIFTA WR is listed as prescription under BLA 022505; tesamorelin was originally approved on November 10, 2010. | Geref remains in FDA’s Discontinued Drug Product List. FDA’s 2013 finding that withdrawal was not for safety or effectiveness reasons was not a current marketing approval. |
| FDA-labeled use | EGRIFTA WR is indicated only to reduce excess abdominal fat in HIV-infected adults with lipodystrophy. | Geref 0.5 mg and 1.0 mg vials were historically indicated for idiopathic growth hormone deficiency in children with growth failure. A separate 0.05 mg ampule was indicated to evaluate pituitary somatotroph growth-hormone secretion. |
| Evidence directly relevant to abdominal fat | In a 404-participant trial in people with HIV on antiretroviral therapy and excess abdominal fat, visceral adipose tissue changed by -10.9% with tesamorelin versus -0.6% with placebo at six months. It is not a general-population result. | Geref records describe pediatric growth-failure treatment and pituitary testing, not HIV-associated abdominal-fat reduction. The reviewed sources establish no head-to-head outcome trial. |
| General weight-loss claim | The EGRIFTA WR label says it is not indicated for weight-loss management because it has a weight-neutral effect. Its abdominal-fat indication must not be generalized to overall weight loss. | The former Geref indications were not general weight-loss indications. FDA’s 2024 advisory-committee material also states that no growth hormone secretagogue has been approved to treat adult- or childhood-onset growth hormone deficiency in adults. |
| Safety information that has current labeling | Current labeling warns about malignancy, elevated IGF-1, fluid retention, glucose intolerance or diabetes, hypersensitivity, injection-site reactions, and critical illness. It lists specified hypothalamic-pituitary-axis disruption, active malignancy, hypersensitivity, and pregnancy as contraindications. | The 2013 withdrawal finding is not a modern safety label or evidence of safety in other populations. The reviewed official sources supply no current FDA-approved sermorelin label. |
| Longer-term and treatment-boundary limits | Long-term cardiovascular safety is not established, and the label reports no adherence benefit for antiretroviral therapy. Trial improvement was rapidly lost after a switch to placebo. | EMD Serono notified FDA of 2008 discontinuations; FDA withdrew both NDAs effective June 18, 2009. This history does not support anti-aging, body-composition, or general-adult claims. |
Swipe the table horizontally to read both columns.
Tesamorelin evidence is focused, not a general body-composition finding
The 404-participant randomized, blinded trial followed HIV-infected participants with excess abdominal fat during antiretroviral therapy. Its primary endpoint was visceral adipose tissue. At six months, that measure fell more with tesamorelin than placebo, while limb and abdominal subcutaneous fat did not change. Continued tesamorelin through 12 months was associated with about an 18% visceral-fat reduction; the initial improvement was rapidly lost after switching to placebo.
The EGRIFTA WR indication is limited to excess abdominal fat in HIV-infected adults with lipodystrophy. It is not indicated for weight-loss management, is weight neutral, has no established long-term cardiovascular safety, and has no evidence of improved adherence to antiretroviral therapy.[1][5]
What the Geref history does and does not mean
FDA identifies two former Geref applications held by EMD Serono: a 1997 pediatric-treatment product and a 1990 pituitary-evaluation product. EMD Serono notified FDA of discontinuation in 2008; FDA withdrew the two NDAs effective June 18, 2009. In 2013, after reviewing records, literature, and potential postmarketing events, FDA found the products were not withdrawn for safety or effectiveness reasons.
The finding is narrow. It keeps Geref in the Discontinued Drug Product List and permits consideration of qualifying abbreviated applications. It does not say sermorelin is currently marketed, provide a current label, or substantiate anti-aging, abdominal-fat, or general weight-loss use.[3][4][7]
Safety discussion requires product-specific context
For tesamorelin, current labeling is the relevant safety source. It covers elevated IGF-1, glucose intolerance or diabetes, fluid retention, hypersensitivity, and injection-site reactions. By week 26, 5% of tesamorelin-treated participants versus 1% of placebo participants had HbA1c at or above 6.5%; the label reports a hazard ratio of 3.3, 95% confidence interval 1.4 to 9.6. These figures do not predict an individual outcome.
The label contraindicates tesamorelin in active malignancy, pregnancy, known hypersensitivity, and specified hypothalamic-pituitary-axis disruption. It says effects of prolonged IGF-1 elevation are unknown. A discontinued-product finding cannot resolve present-day sermorelin safety questions or transfer tesamorelin safety information to another population.[1][3]
Sources and references
Source scope matters: a drug label, trial record, and cell study answer different questions.
- [1] EGRIFTA WR (tesamorelin) Prescribing Information
Official drug label (DailyMed/FDA) · Source date: 2026-07-29
- [2] Purple Book Product Details: Egrifta
FDA biologics database · Source date: Not specified
- [3] Determination That GEREF (Sermorelin Acetate) Injection Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
Federal Register notice (FDA) · Source date: 2013-03-04
- [4] Orphan Drug Designations and Approvals: Sermorelin Acetate (Geref)
FDA orphan-drug database · Source date: Not specified
- [5] Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension
Primary randomized controlled trial (PubMed) · Source date: 2010-03-01
- [6] A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation
Primary randomized controlled trial (PubMed) · Source date: 2005-08-12
- [7] December 4, 2024 Meeting of the Pharmacy Compounding Advisory Committee
FDA advisory committee briefing material · Source date: 2024-12-04
Frequently Asked Questions about Tesamorelin and Sermorelin
Clear answers with the same evidence limits used throughout this page.
Is tesamorelin FDA-approved for weight loss?
No. EGRIFTA WR is indicated for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. Its label specifically says it is not indicated for weight-loss management because it has a weight-neutral effect.[1]
Is sermorelin currently FDA-approved as Geref?
The former Geref products were discontinued and FDA withdrew their NDAs effective June 18, 2009. FDA later determined the products had not been withdrawn from sale for safety or effectiveness reasons, but that is not the same as a current marketed product approval.[3]
Did tesamorelin reduce overall body weight in its registration studies?
The label describes EGRIFTA WR as weight neutral. The pivotal trial’s primary outcome was visceral adipose tissue in HIV-infected people with excess abdominal fat, not general body-weight reduction.[1][5]
Can Geref’s discontinuation be interpreted as proof that sermorelin is safe?
No. FDA’s finding is limited to why those former products were withdrawn from sale. It does not replace a current product label, establish safety in a new population, or demonstrate safety for unstudied goals.[3]
Keep learning
Understand the evidence before the claim.
Explore the educational library, not a shopping catalog.